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Abstract 
Background: An oral sugar test (OST) using Karo® Light Corn Syrup has been developed in the USA as a field test for 
the assessment of insulin dysregulation in horses but the syrup is not available in Scandinavian grocery stores. The aim 
of the study was to compare the results of a modified OST between horses with equine metabolic syndrome (EMS) 
and healthy horses using a Scandinavian commercially available glucose syrup (Dansukker glykossirap). In addition, 
the effect of breed and the repeatability of the test were evaluated. In the present study, clinically healthy horses (7 
Shetland ponies, 8 Icelandic horses, 8 Standardbred horses) and 20 horses of various breeds with EMS underwent the 
modified OST test. The Icelandic horses and Shetland ponies underwent the OST twice. Insulin and glucose data from 
the OST were used to calculate peak insulin concentration (PeakINS), time to peak insulin concentration (T-peakINS), 
area under the curve for insulin (AUCINS) and glucose (AUCGLU) as well as whole body insulin sensitivity index (ISICOMP).
Results: Compared to the healthy group, the EMS group had 6–7 times higher geometric mean for PeakINS and 
AUCINS and 8 times lower geometric mean for ISICOMP. The EMS group had a delayed T-peakINS compared to the 
healthy group. There was no effect of breed in the group of healthy horses on PeakINS, T-peakINS, AUCINS, AUCGLU and 
ISICOMP. Coefficient of variation for repeated tests was 19.8, 19.0 and 17.6 % for PeakINS, AUCINS and ISICOMP respectively.
Conclusions: The results of the present study demonstrate that the modified OST appears to be a practical and use-
ful diagnostic tool for assessment of insulin dysregulation in the horse. However, to make it possible to establish the 
most appropriate sampling interval and to evaluate the accuracy of the modified OST, further studies in horses with a 
variable degree of insulin resistance are needed, where results from the modified OST are compared with quantitative 
measurements for IS.
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Background
Equine metabolic syndrome (EMS) refers to a group of 
clinical abnormalities including generalized obesity and/
or regional adiposity, insulin resistance (IR) and hyper-
insulinemia [1]. Postprandial hyperinsulinemia is a risk 
factor for development of laminitis [2–7], and since EMS 
is a rising concern in the equine population worldwide, 
it is important to create appropriate diagnostic tests 
for abnormalities in insulin regulation. In humans, glu-
cose and insulin data from an oral glucose tolerance test 
(OGTT) can be used to calculate surrogate estimates for 
insulin sensitivity (IS) that are well correlated to IS quan-
tified by the euglycemic hyperinsulinemic clamp (EHC) 
[8–10]. The composite whole-body insulin sensitivity 
index (ISICOMP), also called the Matsuda index, is a com-
monly used OGTT-derived estimate for IS in humans 
[10]. The use of ISICOMP as an estimate for IS in the horse 
has recently been evaluated against quantitative measure-
ments of IS [11]. Despite these relationships OGTT does 
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not measure IS per se. Instead, it is a test in which both 
glucose disposal and insulin secretion are stimulated but 
the test is influenced by factors such as gastric emptying, 
degree of hepatic glucose trapping, β-cell responsiveness 
and incretin effects [12].
Due to the association between hyperinsulinemia and 
laminitis in the horse [13], identification of individuals 
with an exaggerated postprandial insulin response using 
OGTT may enable better management of horses and 
ponies at risk for pasture-associated laminitis. An alter-
native to the OGTT, where glucose is used as the only 
carbohydrate source, is the recently developed oral sugar 
test (OST) [14]. This test uses a standardized amount 
of Karo® light corn syrup, which is composed of differ-
ent unknown carbohydrates. Karo® light corn syrup is, 
however, not available in Scandinavian grocery stores. 
The aim of the present study was therefore to compare 
the results of a modified oral sugar test (OST), using a 
Scandinavian commercially available glucose syrup (Dan-
sukker glykossirap), in a group of healthy horses and in 
horses with EMS. In addition, the effect of breed on the 
test result and the repeatability of the test were studied in 
clinically healthy horses.
Methods
Horses
The study was approved by the Ethical Committee for 
Animal Experiments, Uppsala, Sweden. Twenty-three 
clinically healthy horses and 20 horses with EMS were 
included in the study. The clinically healthy horses were 
seven Shetland ponies, eight Icelandic horses and eight 
Standardbred horses. Inclusion criteria for these horses 
were a body condition score (BCS) of ≤6.5 (scale 1–9) 
[15], a cresty neck score (CNS) of ≤3.0 (scale 0–5) [16], 
normal findings on clinical examination, no history of 
laminitis based on veterinary information and a nor-
mal plasma ACTH concentration. The Icelandic horses 
were used for leisure riding whereas the Standardbred 
horses and Shetland ponies were sedentary horses. The 
horses with EMS were two Fjord horses, one Swedish 
warmblood, ten Icelandic horses, two Shetland ponies, 
one Welsh Cob, one Highland pony, one Swedish riding 
pony, one crossbreed horse and one crossbreed pony. 
The horses with EMS were recruited from a group of 
horses referred for an extended evaluation of EMS at 
the University Animal hospital, Swedish University of 
Agricultural Sciences. Criteria for inclusion were IR, 
defined as a M/I ratio of ≤3.5 calculated from an EHC, 
and a normal plasma ACTH. In addition, horses had to 
have either ≥1 previous episode of laminitis not asso-
ciated with other predisposing conditions or a CNS >3 
[16]. Also, horses eligible to participate had no signifi-
cant findings on clinical examination, were fed a rough-
age based diet without grain supplementation and had 
no ongoing episode of laminitis. Physical characteristics 
for the two groups of horses are reported in Table 1. All 
horses were privately owned except for the clinically 
healthy Standardbred horses, which belonged to the 
Swedish University of Agricultural Sciences research 
herd. All horses in the study were fed a hay or haylage 
diet supplemented with minerals and six of the Icelan-
dic horses were feed 50–100 g of grain 3–5 times/week 
as a treat. Horses were housed in individual box stalls 
and allowed daily turnout in a dirt or a sand paddock. 
None of the horses had been at grass pasture for at least 
2 month prior to testing.
Experimental design
The healthy horses were examined in their home envi-
ronment whereas the horses diagnosed with EMS were 
examined at the large animal clinic at the Swedish Uni-
versity of Agricultural Sciences after an acclimatization 
period of 2 days. All horses in the study were examined 
once with the modified OST. The Icelandic horses and 
Shetland ponies in the healthy group were examined 
twice with 8 days in between, to assess the repeatability 
of the OST. Horses in the EMS group were tested with 
an EHC 24 h after the OST. Both the OST and the EHC 
commenced after 12 h of feed withdrawal overnight but 
with free access to water.
Table 1 Baseline physical characteristics of  horses in  healthy (n =  23) and  equine metabolic syndrome (EMS) (n =  20) 
groups
Data are presented as mean ± standard deviation (SD) (range)
Means with different superscript letters within column differ at P < 0.02
Group Age (years) Body weight (kg) Body condition score (1–9) Cresty neck score (0–5)
EMS (n = 20) 13.9 ± 4.6 (5–22)a 395 ± 117 (124–558)a 6.9 ± 1.1 (5.5–9.0)a 3.7 ± 0.6 (2.5–5.0)a
Healthy (n = 23)
 Shetland pony (n = 7) 3.9 ± 2.7 (1–9)c 152 ± 29 (115–194)b 5.6 ± 0.6 (5.0–6.5)b 2.6 ± 0.4 (2.0–3.0)b
 Icelandic horse (n = 8) 7.0 ± 2.0 (5–10)bc 342 ± 21 (298–360)ac 6.0 ± 0.4 (5.5–6.5)ab 2.6 ± 0.2 (2.5–3.0)b
 Standardbred horses (n = 8) 10.5 ± 4.7 (5–20)ab 507 ± 56 (441–595)d 5.0 ± 0.5 (4.5–5.5)b 2.0 ± 0.5 (1.5–2.5)b
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OST—oral sugar test
The day before the OST an intravenous catheter (Intran-
ule, 2.0 × 105 mm. Vygon, Ecouen, France) was inserted 
aseptically into one of the jugular veins under local anes-
thesia (EMLA, AstraZenica AB, Södertälje, Sweden). On 
the morning of the OST, Dan Sukker Glykossirap (Nordic 
Sugar A/S, Copenhagen, Denmark) was syringed per os 
at a dosage of 0.2 ml/kg body weight, providing 216 mg/
kg BW of saccharides (Table 2). Blood samples were col-
lected from the jugular catheter into evacuated tubes 
(Vacuette 9 ml, Greiner Bio-One GmbH, Kremsmünster, 
Austria) containing lithium heparin, immediately before 
(−5 min), and at 30, 60, 90, 120, 150 and 180 min after 
the oral administration of syrup. After collection of each 
blood sample the catheter line was immediately flushed 
with 10  ml 0.9  % sterile saline solution. Sample tubes 
were centrifuged for 10 min at 2700×g and plasma was 
subsequently harvested and stored at −80 °C until analy-
sis of plasma glucose and plasma insulin.
Insulin and glucose data from the OST were used to cal-
culate the following variables: Peak insulin concentration 
(PeakINS), time to peak insulin concentration (T-peakINS), 
area under the curve for insulin (AUCINS), area under 
the curve for glucose (AUCGLU) and composite whole-
body insulin sensitivity index (ISICOMP) [10]. AUCINS and 
AUCGLU were calculated by use of the trapezoid method 
(GraphPad Prism, version 6.0 for windows; GraphPad 
Software Inc, San Diego, CA). ISICOMP was calculated by 
the following formula: 1000
/√
(G · I) · (MG ·MI), where 
G = baseline glucose concentration, I = baseline insulin 
concentration, MG = mean glucose concentration during 
the OST and MI  =  mean insulin concentration during 
the OST. A numerator of 1000 was used in the formula, 
to transform the data into manageable values.
EHC—euglycemic hyperinsulinemic clamp
For horses in the EMS group, a second intravenous cath-
eter (Intranule, 2.0 ×  105  mm. Vygon, Ecouen, France) 
was inserted into the contralateral jugular vein after the 
OST examination. On the morning of the following day 
blood samples for the determination of baseline con-
centrations of plasma glucose and plasma insulin were 
drawn from one of the intravenous catheters immedi-
ately before (−10, −5, and −1 min) the start of the EHC. 
The EHC technique has previously been described for 
use in horses [17, 18]. Briefly, a continuous rate infusion 
of glucose (Glucose Fresenius Kabi 500 mg/ml, Fresenius 
Kabi AB, Uppsala, Sweden) and recombinant human 
insulin (Humulin Regular, Eli Lilly Sweden AB, Solna, 
Sweden) was initiated through one of the jugular cath-
eters, using a multi-channel volumetric infusion pump 
(Colleague, Volumetric infusion pump, Baxter Health-
care SA, Zurich, Switzerland). The infusion rate for insu-
lin was constant at 3 mU/kg/min and a variable rate of 
glucose was infused to maintain blood glucose concen-
tration at euglycemia (5  mmol/L) during the 3  h long 
infusion. The glucose infusion rate was adjusted if the 
concentration deviated by more than 0.2  mmol/L from 
euglycemia. Blood samples were obtained every 5  min 
for analysis of blood glucose using a handheld glucom-
eter (Accu-Check Aviva, Roche Diagnostics Scandinavia 
AB, Bromma, Sweden) and every 10 min throughout the 
EHC for subsequent determination of plasma glucose 
(10 min intervals) and plasma insulin (20 min intervals). 
After collection of each blood sample, the catheter line 
was immediately flushed with 10 ml 0.9 % sterile saline 
solution.
The first 120 min of the EHC were considered an equi-
libration period. Glucose and insulin data from the final 
60 min (steady-state) were used for calculation of insulin 
sensitivity (M/I ratio). The M/I ratio was calculated for 
each 20-min interval where M is the mean glucose infu-
sion rate and I is the plasma insulin concentration for the 
interval. The M/I60 is the mean of the three M/I ratios 
during steady state [17].
Analysis of blood samples
Plasma glucose concentrations were measured enzymati-
cally with an automated clinical chemistry analyzer (YSI 
2300 Stat Plus Analyzer, YSI Incorporated, Yellow Spring, 
Ohio). Endogenous equine plasma insulin concentra-
tions from the OST were determined using a commer-
cial equine-optimized ELISA (Mercodia Equine Insulin 
ELISA, Mercodia AB, Uppsala, Sweden) evaluated for 
use in horses [19] and insulin levels were controlled with 
a commercial kit (Mercodia Animal Insulin Control 
(Low, Medium, High), Mercodia AB, Uppsala, Sweden). 
Plasma insulin concentrations from the continuous rate 
infusion of recombinant human insulin during the EHC 
procedures were determined using a commercial human 
ELISA (Mercodia Insulin ELISA, Mercodia AB, Uppsala, 
Sweden) and a commercial kit (Mercodia Diabetes Anti-
gen Control (Low, High)/Human, Mercodia AB, Uppsala, 
Sweden) was used as a control. All analyses of plasma 
glucose and insulin were performed in duplicate. The 
mean intra-assay CVs for glucose, equine insulin (equine-
optimized ELISA) and human insulin (human ELISA) 
Table 2 Chemical composition of  the Dan Sukker Glykos-
sirap
Product specification | PS 236654-1.3EN. Nordic Sugar A/S, Copenhagen, 
Denmark
Dry mat-
ter (%)
Glucose 
(%)
Maltose 
(%)
Maltotri-
ose (%)
Other 
sugars 
(%)
Density 
(20 °C)
77 12 11 10 44 1.40 kg/L
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were 0.4, 2.7 and 2.7 % respectively, as determined from 
duplicate analyses.
Statistical analysis
All data were analyzed in JMP® Pro 11.0.0. (SAS Institute 
Inc., Cary, North Carolina, USA). Differences in plasma 
glucose and insulin concentrations for the healthy and 
the EMS groups were compared at different time points 
during the OST, by use of a 2-way ANOVA for repeated 
measures. Differences in physical characteristics (age, 
BCS, CNS and body weight) and OST derived calcu-
lated variables (AUCGLU, AUCINS, ISICOMP, PeakINS and 
T-peakINS) were compared between breeds and between 
the healthy and EMS groups by use of an independent 
t test or a 1-way ANOVA as appropriate. Differences in 
calculated variables for repeated OST tests were com-
pared by use of a paired t test. The repeatability of the 
OST was determined by the mean coefficient of variation 
(mean CV), the intraclass correlation coefficient (ICC) 
and the repeatability coefficient (RC). The ICC was calcu-
lated according to the formula 1−Sw2/(sb2 + Sw2) and the RC 
was calculated as 2.77Sw, where Sw2 is the within subject 
variance and sb2 is the between subject variance calculated 
from the analysis of variance table of a 1-way ANOVA 
[20]. Values of P < 0.05 were considered as significant for 
all analyses. If residuals were not normally distributed 
data were logarithmically transformed. Logarithmically 
transformed data were then expressed as the geometric 
mean ± 95 % CI on the original scale after back transfor-
mation. All other results were expressed as mean ± SD, 
whereas data for age, body weight, BCS and CNS were 
additionally presented with the range.
Results
All horses included in the study fulfilled the inclusion 
criteria for the separate groups. All horses tolerated the 
administration of syrup well. The loss of syrup was neg-
ligible comprising the small amount that got stuck to the 
outside of the syringe during administration.
Comparison of EMS and healthy groups
All horse in the EMS group were defined as insulin resist-
ant by a M/I60 of <3.5 (μg/kg/min)/(mU/L). Fourteen 
of 20 included horses with EMS had a severe IR i.e. M/
I60  <  2.0 (μg/kg/min)/(mU/L). Sixteen of the 20 horses 
included in the EMS group had previous episodes of lam-
initis. The EMS group had a higher mean CNS compared 
to the breeds included in the healthy group (P < 0.0004). 
Mean BCS was higher in the EMS group compared to 
the Standardbred horses and Shetland ponies of the 
healthy group (P  <  0.010), but no difference was found 
between the EMS group and the healthy Icelandic horses 
(P = 0.074) (Table 1).
There was an overall effect of time between the group 
of healthy horses and EMS horses during the OST for 
insulin (P < 0.0001) but not for glucose (P = 0.178). An 
overall interaction between group of horses (clinically 
healthy vs EMS) and time was identified for both insulin 
(P < 0.0001) and glucose (P = 0.003) (Fig. 1).
Compared to the healthy group, the EMS group 
had 6–7 times higher geometric mean for PeakINS 
(P < 0.0001) and AUCINS (P < 0.0001) and 8 times lower 
geometric mean for ISICOMP (P < 0.0001) (Fig. 2). Horses 
in the healthy group reached the maximum insulin con-
centration (T-peakINS) on average 69 ± 25 min from the 
start of the OST. Horses in the EMS group had delayed 
insulin peak compared to the healthy group (P = 0.007) 
with an average of 92 ± 27 min from the start of OST. In 
the healthy group geometric means (95 % CI) for insulin 
were 222 (172–288) ng/L and 206 (159–267) ng/L at the 
60 and 90 min sampling respectively. For the EMS group 
the geometric means (95 % CI) for insulin for the corre-
sponding time points were 1329 (1006–1756) ng/L and 
1452 (1099–1919) ng/L, respectively.
Breed comparison
There was no effect of breed on AUCGLU, AUCINS, Peak-
INS, ISICOMP and T-peakINS in the group of healthy horses 
(Table 3).
Repeatability testing
The AUCGLU, AUCINS, PeakINS, ISICOMP and T-peakINS 
did not significantly differ between repeated tests per-
formed in the group of healthy horses (Table 4). Among 
the variables derived from the OST, the AUCGLU had the 
best combination of repeatability measures i.e., a low 
mean CV, a high ICC and a relatively small RC. In con-
trast, PeakINS and T-peakINS had higher mean CVs as well 
as larger RC in relation to each of the means. Further, the 
PeakINS had a similar ICC as AUCGLU, whilst T-peakINS 
had the lowest ICC of all calculated variables.
Discussion
A modified OST test was developed and evaluated using 
a Scandinavian commercially available glucose syrup 
(Dan Sukker Glykossirap). Higher OST glucose and insu-
lin plasma concentrations and accordingly lower ISICOMP 
as well as higher AUCGLU, AUCINS and PeakINS were 
found in the EMS group compared to the healthy group. 
Moreover, the calculated parameters from the OST had 
moderate to high repeatability and there was no effect 
of breed on the test results. These results show that the 
modified OST appears to be a practical and useful diag-
nostic tool for assessment of dysinsulinemia in the horse.
It has been suggested that the OGTT and OST more 
closely mimic the glucose and insulin dynamics during 
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Fig. 1 Plasma glucose (a) and plasma insulin (b) concentrations measured during the OST in healthy (n = 23) and EMS (n = 20) groups. Data are 
presented as mean ± SD for plasma glucose and as geometric mean, 95 % confidence interval for plasma insulin. *Groups differ at P < 0.0001. 
#Groups differ at P < 0.0036. OST oral sugar test; EMS equine metabolic syndrome; SD standard deviation
Fig. 2 AUCGLU (a), AUCINS (b), PeakINS (c) and ISICOMP (d) values for OST performed in healthy (n = 23) and EMS (n = 20) groups. Horizontal lines pre-
sent mean, SD for AUCGLU; and geometric mean, 95 % confidence interval for AUCINS, PeakINS and ISICOMP. P < 0.05 represents statistical differences. 
OST oral sugar test; AUCGLU area under the curve for glucose; AUCINS area under the curve for insulin; PeakINS peak concentration for insulin; ISICOMP 
composite whole-body insulin sensitivity index; EMS, equine metabolic syndrome; SD standard deviation
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physiological conditions than the EHC and the frequently 
sampled IV glucose tolerance test (FSIGTT). However, 
it is important to recognize that glucose and insulin 
responses after oral glucose delivery are not equivalent 
to insulin sensitivity. The glucose and insulin response 
after oral administration of glucose are dependent on fac-
tors such as gastric emptying, absorption, glucose uptake 
in the liver, incretin effects, insulin secretion and clear-
ance as well as insulin sensitivity [12]. Thus, the OGTT 
and OST provide information about the efficiency of the 
homeostatic mechanisms including insulin-dependent 
mechanisms to restore blood glucose concentration to 
basal levels but not IS/IR per se. Nevertheless, several 
studies in humans, but also in the horse, have used differ-
ent surrogate indices based on dynamic data from OGTT 
in order to estimate IS [8–11]. The most commonly used 
index in humans, ISICOMP, reflects a composite estimate 
of both hepatic and peripheral insulin sensitivity based 
on fasting glucose and insulin data as well as the mean 
of glucose and insulin values obtained during the OGTT. 
The square-root conversion in the formula is used to cor-
rect for non-linear distribution of data in relation to the 
IS determined by the EHC [10]. Studies in humans and 
horses have shown that ISICOMP has a relatively good 
linear correlation to quantitative measurements of IS 
obtained by the EHC and the surrogate index therefore 
provides a reasonable estimate of IS [10, 11].
Compensatory hyperinsulinemia can develop in 
horses with IR [21, 22] by two mechanisms: increased 
insulin secretion from the ß-cells in the pancreas and 
reduced insulin clearance by the liver [21, 23–26]. This 
hyperinsulinemia is more pronounced and thereby eas-
ier to detect after feed intake compared to pre-prandial 
conditions [27, 28]. The OST is a dynamic test that mim-
ics a feeding situation and makes it possible to study 
postprandial hyperinsulinemia under controlled condi-
tions. In the present study horses in the EMS group had 
higher plasma insulin concentrations at all time points 
during the OST compared to the healthy group. The 
higher insulin response in the EMS group resulted in 
higher AUCINS, PeakINS and lower ISICOMP compared to 
the healthy group. In contrast, plasma glucose concen-
trations only differed between the healthy and the EMS 
group at 120, 150 and 180 min. Repeated blood sampling 
is necessary for calculation of AUCINS, AUCGLU and ISI-
COMP, making these parameters less useful during field 
conditions. Instead, PeakINS requires only a single sam-
ple, which reduces the costs for laboratory analyses as 
well as the time spent on sampling in the field during the 
test.
Table 3 Calculated variables and  measures for  the oral sugar test (OST) in  healthy Shetland ponies (n =  7), Icelandic 
horses (n = 8) and Standardbred horses (n = 8)
Data are presented as mean ± SD for AUCGLU and AUCINS; and as geometric mean (95 % confidence interval) for PeakINS and ISICOMP
AUCGLU area under the curve for glucose; AUCINS area under the curve for insulin; ISICOMP composite whole-body insulin sensitivity index; PeakINS peak concentration for 
insulin; T-peakINS time to peak concentration for insulin; SD standard deviation
Shetland ponies Icelandic horses Standardbred horses P value
AUCGLU (mmol/L × min) 1071 ± 136 1239 ± 167 1100 ± 96 0.055
AUCINS (ng/L × min) 32,235 ± 14,797 29,130 ± 14,655 26,967 ± 7600 0.728
ISICOMP 2.2 (1.5–3.2) 2.6 (1.8–3.7) 2.8 (1.9–4.0) 0.608
PeakINS (ng/L) 301 (203–446) 237 (164–342) 259 (179–374) 0.652
T-peakINS (min) 56 ± 27 75 ± 23 75 ± 23 0.234
Table 4 Calculated variables and measures of repeatability for the oral sugar test (OST) in 15 healthy horses (7 Shetland 
ponies, 8 Icelandic horses)
Data are presented as mean ± standard deviation (SD)
AUCGLU area under the curve for glucose; AUCINS area under the curve for insulin; ISICOMP composite whole-body insulin sensitivity index; PeakINS peak concentration for 
insulin; T-peakINS time to peak concentration for insulin; mean CV mean coefficient of variation; ICC intraclass correlation coefficient; RC repeatability coefficient
Test 1 Test 2 P value Mean CV (%) ICC RC
AUCGLU (mmol/L × min) 1161 ± 171 1153 ± 116 0.823 6.7 0.79 237.7
AUCINS (ng/L × min) 30,579 ± 14,276 31,706 ± 15,526 0.623 16.9 0.91 16,556.4
ISICOMP 2.7 ± 1.5 2.8 ± 1.6 0.912 17.3 0.85 2.1
PeakINS (ng/L) 309 ± 190 308 ± 153 0.976 18.3 0.83 255.5
T-peakINS (min) 66 ± 26 74 ± 34 0.334 18.5 0.64 60.7
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For the USA-developed OST [14] researchers found 
that peak concentrations for insulin was recorded at 
blood sampling at 60 or 90  min after syrup administra-
tion. Hence, the time interval between 60 and 90  min 
after sugar administration is recommended for single 
blood sampling for measurements of peak insulin con-
centrations. In the present study, there was a longer mean 
time to peak insulin in the EMS group (92  ±  27  min) 
compared to the healthy group (69 ± 25 min). Neverthe-
less, plasma insulin concentration differed between the 
healthy and the EMS group at all time points during the 
OST and there was no overlap of confidence intervals. 
This suggests that the time frame for single blood sam-
pling could be extended, making the test protocol more 
time flexible. The largest difference in plasma insulin con-
centrations between the two groups of horses occurred 
at sampling times between 60 and 150 min. However, the 
majority of horses included in the EMS group of the pre-
sent study had a severe IR, as determined by the EHC. 
Severe IR is associated with a pronounced compensatory 
β-cell response as well as decrease in insulin clearance 
[22, 25], leading to a prolonged insulin response during 
the OST. On the other hand, a horse in an early stage of 
disease with a mild to moderate degree of IR, is likely to 
have a shorter and less prominent insulin response. Thus, 
if a blood sample is taken later during the OST in these 
horses (for example at 150  min) the insulin concentra-
tion may then have decreased to a level seen in a normal 
horse. The most optimal time point for sampling in order 
to distinguish normal horses from those with insulin dys-
regulation, can therefore not be concluded from the pre-
sent study since it would have required a larger number 
of horses with a wider range of IR and β-cell responses.
The Karo® Light Corn Syrup is not available in Scandi-
navian grocery stores wherefore the agreement between 
the USA-developed OST and the modified OST could 
not be assessed. For the modified OST a dose of 0.2 ml/
kg syrup is used, providing 216  mg saccharides/kg of 
body weight compared to 0.15  ml/kg of syrup for the 
USA developed OST that is estimated to provide the 
horse with 150 mg/kg of body weight of dextrose-derived 
digestible sugars. The total dose of sugar is thereby 44 % 
higher for the modified test. The glucose and insulin 
response after administration of syrup is not only influ-
enced by the total amount of sugar but also the relative 
composition of the different sugar types. Information 
about the composition of the Karo® Light Corn Syrup is 
withheld by the manufacturer, which therefore makes it 
difficult to design an identical test for the Scandinavian 
market. Another aspect that further complicates compar-
isons between the two tests is that different assays have 
been used for measurement of plasma insulin (Coat-A-
Count Insulin RIA vs Mercodia Equine Insulin ELISA). 
Earlier performed work [19] showed that results were 
in good agreement between these two assays for sam-
ples with equine insulin concentrations <150  µU/ml, 
but for samples with higher insulin concentrations the 
agreement between assays was poor [29]. The calculated 
conversion factor for equine insulin from mU/L, deter-
mined with the radioimmunoassay (RIA) method, to 
the quantitative unit ng/L, determined with the equine 
specific ELISA is 10 [19]. The cutoff for dysinsulinemia 
for the USA developed OST is >60 mU/L (measured by 
the RIA) at sampling at 60–90 min [30, 31], correspond-
ing to >600  ng/L for insulin concentrations measured 
by the equine ELISA. In the present study, 21 of the 23 
horses in the healthy group had plasma insulin concen-
trations <400  ng/L at the 60  min sampling and at the 
90  min sampling all healthy horses had plasma insulin 
concentrations <400  ng/L. In the EMS group 19 of 20 
horses had plasma insulin concentrations >600 ng/L at 60 
and 90 min. If the same sampling interval is used for the 
modified OST as for the USA developed OST (i.e. 60–90 
min) it seems reasonable to use the same cut off values 
for the two tests.
No differences were found between breeds for any of 
the OST calculated variables (AUCGLU, AUCINS, ISICOMP, 
PeakINS and T-peakINS). Previous studies have shown dif-
ferences in IS between healthy horses of different breeds 
using other diagnostic tests such as the CGIT [32] or the 
FSIGTT [28]. A small sample in combination with a rela-
tively large within breed variation could possibly explain 
why no effect of breed was found in the present study. 
Another aspect is that only the Icelandic horses were 
exercised and used for leisure riding whereas the remain-
der (Shetland ponies and Standardbred horses) were 
sedentary horses. Since exercise can affect the degree 
of IS [33, 34], it is possible that the outcome would have 
been different if the degree of activity had been similar 
between breeds. Another explanation might be that the 
test is not sensitive enough to detect small differences in 
IS between different breed populations.
One limitation of the present study is that one group 
of horses (the EMS group) was tested during hospi-
talization whereas all other horses were tested in their 
home environment. In a previous study [35] no effect of 
housing and diet on results from the OST were found. 
The EMS horses in our study were acclimatized 48  h 
prior to testing at the large animal clinic and horses 
were only fed their own hay or haylage in order to 
minimize the possible effect of housing and feeding. 
Another limitation is that normal IS evaluated by EHC 
was not used as inclusion criteria for the healthy group. 
Whereas the IS of the Standardbred horses is known to 
be normal based on information from previous research 
projects where the horses’ IS have been quantified (data 
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not shown), the IS of the privately owned control horses 
is unknown. However, all control horses had normal 
fasting plasma insulin and glucose concentrations sug-
gesting normal IS.
The definition of general obesity has varied among 
studies, e.g., BCS  >  6 [5], BCS  ≥  7 [23, 36], BCS  ≥  8 
[16]. Another study suggested BCS 7–7.5 as overweight 
but not obese [16]. The Henneke score [15] is origi-
nally adapted for use in Quarter Horses but there are no 
studies evaluating how well this scoring system agrees 
between different breeds. In addition, there seems to be 
breed variations as well as seasonal variations in CNS 
[37]. There is thus no consensus on how overweight or 
abnormal local adiposity should be defined for different 
breeds of horses. It is possible that the inclusion criteria 
for BCS and CNS among the normal horses in the pre-
sent study should have used a narrower range. To test the 
hypothesis that BCS or CNS among the normal horses 
were associated with fasting insulin concentrations, 
PeakINS or ISICOMP linear regressions were performed. 
These regression models showed no significant correla-
tions (P > 0.160, data not shown) suggesting no effect of 
BCS or CNS on the insulin response or estimates for IS in 
the normal horses.
The CV values for repeated tests in the present study 
varied between 6.7 and 18.5  % for calculated variables, 
where AUCGLU showed the lowest variation between 
tests. Higher intra-assay variability was found for analysis 
of insulin than for glucose in the present study, possibly 
affecting the CV values for the calculated parameters. In 
comparison, a previous study [14] using the USA devel-
oped OST, reported a similar CV for AUCGLU (6.4 %) but 
a higher CV for the AUCINS (45.1 %). One reason for the 
discrepancy of results is that fewer horses were used for 
repeatability testing in the aforementioned study. The 
insulin derived variables from the modified OST were 
generally considered to have a moderate to high repeat-
ability based on CV, ICC and RC. Thus, repeatability of 
the OST appears to be comparable to the calculated vari-
ables from the insulin curve of another non-quantitative 
dynamic tests, the CGIT [32].
Conclusions
The results of the present study demonstrate that the 
modified OST appears to be a practical and useful diag-
nostic tool for assessment of dysinsulinemia in the horse. 
However, to make it possible to establish the most appro-
priate sampling interval and to evaluate the accuracy of 
the modified OST, further studies in horses with a varia-
ble degree of insulin resistance are needed, where results 
from the modified OST are compared with quantitative 
measurements for IS.
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